TORONTO--(BUSINESS WIRE)--May 2, 2006--Biovail Corporation (NYSE:BVF - News; TSX:BVF - News) today announced that Biovail Pharmaceuticals, Inc. (BPI), the Company’s wholly owned U.S. subsidiary, and AstraZeneca Pharmaceuticals LP have entered into an agreement for which BPI’s specialty sales force will promote Zoladex® 3.6mg (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the United States and Puerto Rico.
